Literature DB >> 21963959

Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma.

Mohamad H Imam1, Marina G Silveira, Emmanouil Sinakos, Andrea A Gossard, Roberta Jorgensen, Jill Keach, Alisha C DeCook, Keith D Lindor.   

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently develops in patients with primary biliary cirrhosis (PBC). We determined the mortality of patients with PBC who develop HCC, and which interventions (surgery, radiofrequency ablation, chemoembolization, alcohol injection, or transplantation) increase survival times. We investigated whether the Milan criteria predict outcomes of these patients and are effective in selection for liver transplantation.
METHODS: We evaluated data from 38 patients who had a confirmed diagnosis of PBC and HCC between March 1993 and February 2011. Patients were grouped based on whether or not they met the Milan criteria. Survival was assessed using the Kaplan-Meier analysis.
RESULTS: Eighteen of the 38 patients (47.3%) died during the follow-up period; 49.4% survived for 5 years and 31.7% survived for 10 years. Thirty-five patients (92.0%) underwent one or a combination of interventions. Liver transplantation improved survival (risk ratio, 0.06; P < .0001), whereas surgery approached significance in causing deterioration (risk ratio, 2.87; P = .07). Mortality did not appear to be affected by meeting the Milan criteria (P = .84).
CONCLUSIONS: Five- and 10-year survival times for patients with PBC who developed HCC were 49.4% and 31.7%, respectively. Patients who meet the Milan criteria receive liver transplantation as often as those who do not; we did not observe a difference in survival time between groups. Patients with PBC who develop HCC appear to benefit from aggressive therapies.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21963959     DOI: 10.1016/j.cgh.2011.09.013

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  3 in total

1.  Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.

Authors:  Dustin E Bosch; Yoh Zen; Sarag A Boukhar; Yongjun Liu; Lin Cheng; Matthew M Yeh
Journal:  Virchows Arch       Date:  2021-08-20       Impact factor: 4.064

2.  Repeat liver resection for hepatocellular carcinoma complicating primary biliary cirrhosis.

Authors:  Susumu Mochizuki; Hisashi Nakayama; Tokio Higaki; Takao Okubo; Yutaka Midorikawa; Masamichi Moriguchi; Osamu Aramaki; Shintaro Yamazaki; Masahiko Sugitani; Tadatoshi Takayama
Journal:  Int Surg       Date:  2013 Oct-Dec

Review 3.  Current understanding of primary biliary cholangitis.

Authors:  Atsushi Tanaka
Journal:  Clin Mol Hepatol       Date:  2020-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.